Understanding Response and Resistance to Inhibition of Mutant Isocitrate Dehydrogenase in Acute Myeloid Leukaemia

Grant number: 1099160 | Funding period: 2016 - 2018

Completed

Abstract

Acute myeloid leukaemia (AML) is an aggressive cancer of white blood cells and development of novel treatment options is urgently needed. Mutations in enzymes known as isocitrate dehydrogenase (IDH) -1 and -2 are amongst the most common in AML and recent studies strongly suggest that mutant IDH proteins are attractive drug targets. In this proposal we will use advanced genetic tools to comprehensively analyse the role of IDH dysfunction in leukaemia initiation, development and progression.

Related publications (2)

Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells

E Gruber, J So, AC Lewis, R Franich, R Cole, LG Martelotto, AJ Rogers, E Vidacs, P Fraser, K Stanley, L Jones, A Trigos, N Thio, J Li, B Nicolay, S Daigle, AE Tron, ML Hyer, J Shortt, RW Johnstone

2022-08-16

Approximately 20% of acute myeloid leukemia (AML) patients carry mutations in IDH1 or IDH2 that result in over-production of the o..

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia

J So, AC Lewis, LK Smith, K Stanley, R Franich, D Yoannidis, L Pijpers, P Dominguez, SJ Hogg, SJ Vervoort, FC Brown, RW Johnstone, G McDonald, DB Ulanet, J Murtie, E Gruber, LM Kats

2022-07-07

The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the rate-limiting steps in de novo pyrimidine biosy..

University of Melbourne Researchers

Lev Kats